Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
- PMID: 3131471
Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
Abstract
We characterized the immune response in humans after vaccination with a Pseudomonas aeruginosa immunotype 5 O-polysaccharide (O-PS)-toxin A conjugate vaccine. The majority of volunteers responded with an immunoglobulin G (IgG) antibody response on enzyme-linked immunosorbent assay (ELISA) to both the toxin A and the lipopolysaccharide (LPS) components of the vaccine. Maximal titers to both vaccine components were seen 42 days after immunization. Antibody levels remained elevated for at least 14 months after vaccination. The anti-LPS IgG response was predominantly within the IgG1 and IgG2 subclasses, whereas the antitoxin A response was within the IgG1 subclass. There was a gradual elevation of IgG4 antitoxin antibody, with maximal levels seen at 14 months after immunization. No concomitant IgG4 antibody rise to LPS was observed. Immunization evoked a vigorous IgA1 and IgA2 antibody response to LPS, which was long-lived. Only a modest, transient IgA antitoxin A response was noted. Both antitoxin A--neutralizing and opsonic antibodies were elicited by immunization and remained elevated over the 14-month postimmunization period studied.
Similar articles
-
Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine.Eur J Immunol. 1988 Dec;18(12):2073-5. doi: 10.1002/eji.1830181230. Eur J Immunol. 1988. PMID: 3220104
-
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.J Clin Invest. 1987 Jul;80(1):51-6. doi: 10.1172/JCI113062. J Clin Invest. 1987. PMID: 3110215 Free PMC article.
-
Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.Infect Immun. 1988 Jul;56(7):1829-30. doi: 10.1128/iai.56.7.1829-1830.1988. Infect Immun. 1988. PMID: 2454893 Free PMC article. Clinical Trial.
-
Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S644-9. doi: 10.1093/clinids/9.supplement_5.s644. Rev Infect Dis. 1987. PMID: 3120274 Review.
-
Conjugate vaccines against Pseudomonas aeruginosa and malaria.Contrib Microbiol Immunol. 1989;10:166-89. Contrib Microbiol Immunol. 1989. PMID: 2510972 Review. No abstract available.
Cited by
-
Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.Int J Med Microbiol. 2007 Sep;297(5):277-95. doi: 10.1016/j.ijmm.2007.03.012. Epub 2007 Apr 27. Int J Med Microbiol. 2007. PMID: 17466590 Free PMC article. Review.
-
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.Clin Exp Immunol. 2005 Nov;142(2):381-7. doi: 10.1111/j.1365-2249.2005.02925.x. Clin Exp Immunol. 2005. PMID: 16232228 Free PMC article. Clinical Trial.
-
Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.Infect Immun. 1995 May;63(5):1855-62. doi: 10.1128/iai.63.5.1855-1862.1995. Infect Immun. 1995. PMID: 7729895 Free PMC article.
-
Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.Infect Immun. 1999 Mar;67(3):1461-70. doi: 10.1128/IAI.67.3.1461-1470.1999. Infect Immun. 1999. PMID: 10024596 Free PMC article.
-
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.Clin Exp Immunol. 2006 Jan;143(1):132-8. doi: 10.1111/j.1365-2249.2005.02964.x. Clin Exp Immunol. 2006. PMID: 16367944 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous